Edition:
United States

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

28,369.46ZAc
23 Jun 2017
Change (% chg)

414.46 (+1.48%)
Prev Close
27,955.00
Open
27,670.00
Day's High
28,438.00
Day's Low
27,670.00
Volume
1,085,006
Avg. Vol
1,334,204
52-wk High
38,849.00
52-wk Low
25,564.00

APNJ.J

Chart for APNJ.J

About

Aspen Pharmacare Holdings Limited is a South Africa-based supplier and manufacturer of branded and generic pharmaceutical products, as well as infant nutritional and consumer healthcare products. The Company's segments include International, South Africa, Asia Pacific and Sub-Saharan Africa (SSA). Its International business... (more)

Overall

Beta: 0.78
Market Cap(Mil.): R127,596.50
Shares Outstanding(Mil.): 456.44
Dividend: 248.00
Yield (%): 0.89

Financials

  APNJ.J Industry Sector
P/E (TTM): 33.73 14.08 19.12
EPS (TTM): 8.29 -- --
ROI: 5.07 -6.75 -5.05
ROE: 9.14 -6.20 -4.29

Pfizer, Roche and Aspen face South African probe into cancer drug prices

PRETORIA South Africa's competition watchdog has launched an investigation into three drug companies accused of over-charging for cancer medicines, the agency's chief said on Tuesday.

Jun 14 2017

UPDATE 2-Pfizer, Roche and Aspen face South African probe into cancer drug prices

* Aspen denies any wrong doing, committed to constructive engagement

Jun 13 2017

BRIEF-Aspen Pharmacare responds to South African Competition Commission investigation announcement

* Announcement that SACC will be investigating co for suspected abuse of dominance in respect of provision of cancer medication in South Africa

Jun 13 2017

Pfzer, Roche and Aspen face South Africa probe over cancer drug prices

PRETORIA, June 13 South Africa's competition watchdog has launched an investigation into three pharmaceutical companies suspected of charging excessively for cancer medicines, the agency's head Tembinkosi Bonakele said on Tuesday.

Jun 13 2017

French drugmaker Servier challenges 331 mln euro EU antitrust fine

LUXEMBOURG, June 6 French drugmaker Servier urged an EU court on Tuesday to slash a 331 million euro ($372 million) antitrust fine, saying regulators had committed multiple errors when they ruled against the company's pay-for-delay deals with generic rivals three years ago.

Jun 06 2017

BRIEF-Aspen Pharmacare says hasn't raised prices outside regulatory framework

* Further confirms pharmaceutical prices are approved by department of health in terms of single exit price regulatory framework

May 30 2017

Aspen under EU antitrust spotlight over excessive cancer drug prices

BRUSSELS EU antitrust regulators will investigate whether Aspen Pharmacare is charging excessive prices for five key cancer drugs in a move which could lead to a hefty fine for Africa's largest generic drugmaker.

May 15 2017

UPDATE 2-Aspen under EU antitrust spotlight over excessive cancer drug prices

BRUSSELS, May 15 EU antitrust regulators will investigate whether Aspen Pharmacare is charging excessive prices for five key cancer drugs in a move which could lead to a hefty fine for Africa's largest generic drugmaker.

May 15 2017

Aspen under EU antitrust spotlight over excessive cancer drug prices

BRUSSELS EU antitrust regulators will investigate whether Aspen Pharmacare is charging excessive prices for five key cancer drugs in a move which could lead to a hefty fine for Africa's largest generic drugmaker.

May 15 2017

EU regulators to investigate Aspen's drug prices for cancer

BRUSSELS, May 15 EU antitrust regulators will investigate whether South Africa's Aspen Pharmacare pricing practices for five of its cancer medicines violate the bloc's rules against companies abusing their market power.

May 15 2017

More From Around the Web

Earnings vs. Estimates